New process to assess clinical and cost-effectiveness of COVID-19 treatments to get these medicines ...
Read moreUsing Early Access Programs (EAPs) to give patients with life threatening conditions access to medic...
Read moreOur Market Access experts investigate what early access opportunities are available in China to enab...
Read moreThe first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read morePayer value proposition development and understanding evidence requirements to secure pricing and re...
Read moreAlmost a decade after it's inception, what have we learned from the UK early access to medicines sch...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreOur client was seeking market authorisation for one indication and were expected a secondary indicat...
Read moreOur client had in-licenced a hospital drug that they were seeking to launch in the EU, following a r...
Read more